Intervention

aprepitant

ClinicalTrials.gov intervention label

Clinical trials10

Recruiting0

Common conditions7

Lead sponsors shown6

Clinical trials

10 shown

The Role of Substance P on Perception of Breathlessness During Resistive Load BreathingNCT01580423 · 2012-04-01

Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer PatientsNCT00588835 · 2008-03-01

Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical TrialNCT00475085 · 2006-12-01

Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast CancerNCT00719173 · 2005-08-01

Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell TransplantNCT00248547 · 2004-05-01

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)NCT00048607 · 2002-07-30

Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)NCT00048594 · 2002-01-03

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)NCT00035048 · 2001-11-21

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)NCT00034983 · 2001-10-29

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)NCT00035282 · 2001-09-01

Common conditions

Major Depressive Disorder5 Breast Cancer1 Cancer1 Chronic Obstructive Pulmonary Disease1 Nausea1 Nausea and Vomiting1 Tumor1

Leading sponsors

Merck Sharp & Dohme LLC5 Dartmouth-Hitchcock Medical Center1 Joseph Roscoe1 OHSU Knight Cancer Institute1 Radboud University Medical Center1 UNC Lineberger Comprehensive Cancer Center1

Trial status mix

COMPLETED9

TERMINATED1

Phase mix

PHASE36

NA2

PHASE11

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.